P552 Clinical factors associated with ustekinumab therapy persistence in a refractory Crohn’s disease cohort

R Corcoran,N Breslin,B Ryan,A O'Connor,S O'Donnell,S McKiernan,F MacCarthy,C Dunne,K Hartery,D McNamara,D Kevans,

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0682

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab (UST) is a monoclonal antibody that binds to the p40 subunit shared by pro-inflammatory interleukins 12 and 23. UST has demonstrated efficacy for the induction and maintenance of remission in patients with Crohn’s disease (CD). A proportion of patients with CD do not respond to UST at the standard dose of 90 mg every 8 weeks. Methods A multi-centre retrospective study of CD patient who commenced UST therapy at two specialist tertiary referral centres between October 2012 and March 2021 was performed. Patient demographics, baseline characteristics, medication history and disease behaviour were characterised. Duration of UST therapy and UST dose escalation were documented. UST therapy persistence, was considered a proxy for treatment response, and was expressed as time to discontinuation of UST therapy. The study evaluated whether UST dose optimisation was associated with increased UST therapy persistence; and clinical factors associated with UST therapy persistence. Optimised dosing was defined as a dosing regimen of UST 90mg at less than an 8-weekly interval. Statistical analysis was performed using survival analysis and multivariate cox logistic regression with effect of covariates on outcome expressed as odds ratios (OR). Results 133 patients commenced UST during the study period (age [mean, range] 39 years, 16-79; 59% female; disease duration [mean, range] 12.4 years, 1-35). 99% of patients had failed at least 1 biologic and 72 patients (54%) required dose escalation during the study period. The mean duration of UST therapy was 74 weeks (range 2-427). 75 (56%) patients were still receiving UST at end of study period. Survival analysis demonstrated that there was no significant difference in UST persistence between patients receiving standard and optimised UST dosing regimens, p=0.58. Patients with early UST dose optimisation (within 6 months of therapy initiation) had increased UST therapy persistence, p=0.003. A multivariate regression analysis demonstrated that early UST dose optimisation (within 6 months of therapy initiation) was independently associated with a longer time to UST therapy discontinuation (OR 0.31 (95%CI 0.15-0.68), p=0.003). Neither disease duration (OR 1.11, p=0.66), male sex (OR 0.91, p=0.83), concomitant immunomodulator use (OR 1.03, p=0.95), perianal disease (OR 1.09, p=0.85), smoking status (OR 1.16, p=0.68) nor previous surgery (OR 1.47, p=0.33) were independently associated with time to UST therapy discontinuation. Conclusion UST is an effective treatment for CD patients with prior biologic therapy exposure. Optimised UST dosing regimens are frequently utilised in routine clinical practice. There appears to be an increased likelihood of treatment success with early UST dose optimisation.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the influencing factors of the duration of ustekinumab (UST) treatment in patients with refractory Crohn's disease (CD), especially the impact of early dose optimization on the duration of UST treatment. Ustekinumab is a monoclonal antibody that can bind to the p40 subunit shared by the pro - inflammatory cytokines interleukin - 12 and 23, and has been proven to be effective in inducing and maintaining remission in patients with Crohn's disease. However, some patients do not respond to UST at the standard dose (90 mg every 8 weeks). Therefore, the researchers explored through retrospective analysis whether UST dose optimization can improve the treatment duration and identify the clinical factors related to the UST treatment duration.

The research methods include a multi - center retrospective study of CD patients who started UST treatment in two specialized tertiary referral centers from October 2012 to March 2021. Data such as patients' baseline characteristics, drug history, and disease behavior were collected, and the duration of UST treatment and dose adjustment were recorded. The persistence of UST treatment was regarded as a surrogate indicator of treatment response, expressed as the time when UST treatment was stopped. Survival analysis and multivariate Cox proportional - hazards regression models were used in the study to evaluate the impact of covariates on the results, expressed in the form of odds ratio (OR).

The research results show that among 133 patients who started UST treatment, most patients (99%) were ineffective to at least one biologic agent, and 54% of the patients required dose adjustment during the study period. The average duration of UST treatment was 74 weeks. Survival analysis showed that there was no significant difference in UST persistence between patients receiving standard and optimized UST dosing regimens (p = 0.58). However, early UST dose optimization (within 6 months after the start of treatment) was significantly associated with an increase in the duration of UST treatment (p = 0.003). Multivariate regression analysis further confirmed that early UST dose optimization was independently associated with a longer UST treatment duration (OR 0.31, 95% CI 0.15 - 0.68, p = 0.003). Other factors such as disease duration, gender, combined use of immunomodulators, perianal disease, smoking status, or previous surgical history did not independently affect the duration of UST treatment.

The conclusion points out that for CD patients who have previously received biologic agent treatment, UST is an effective treatment option. In routine clinical practice, the optimized dosing regimen of UST is often adopted, and early dose optimization seems to be able to improve the probability of treatment success.